tiprankstipranks
Advertisement
Advertisement
Sparrow Pharmaceuticals Highlights Cortisol Dysregulation Focus in Type 2 Diabetes Research
PremiumPrivate CompaniesSparrow Pharmaceuticals Highlights Cortisol Dysregulation Focus in Type 2 Diabetes Research
1M ago
Sparrow Pharmaceuticals Emphasizes Integrated Approach to Cardiometabolic Disease
Premium
Private Companies
Sparrow Pharmaceuticals Emphasizes Integrated Approach to Cardiometabolic Disease
2M ago
Sparrow Pharmaceuticals Builds Momentum With New Cortisol-Driven Diabetes Data and Scientific Outreach
Premium
Private Companies
Sparrow Pharmaceuticals Builds Momentum With New Cortisol-Driven Diabetes Data and Scientific Outreach
2M ago
Sparrow Pharmaceuticals Launches Educational Series on Cortisol and Cardiometabolic Disease
PremiumPrivate CompaniesSparrow Pharmaceuticals Launches Educational Series on Cortisol and Cardiometabolic Disease
2M ago
Sparrow Pharmaceuticals Advances Clofutriben With New Cortisol Data in Hard‑to‑Treat Type 2 Diabetes
Premium
Private Companies
Sparrow Pharmaceuticals Advances Clofutriben With New Cortisol Data in Hard‑to‑Treat Type 2 Diabetes
3M ago
Sparrow Pharmaceuticals Highlights Interim CAPTAIN-T2D Data on Cortisol in Type 2 Diabetes
Premium
Private Companies
Sparrow Pharmaceuticals Highlights Interim CAPTAIN-T2D Data on Cortisol in Type 2 Diabetes
3M ago
Sparrow Pharmaceuticals Highlights Positive Phase 2a Data for Clofutriben
PremiumPrivate CompaniesSparrow Pharmaceuticals Highlights Positive Phase 2a Data for Clofutriben
3M ago
Sparrow’s Clofutriben Shows Broad Metabolic Gains in Phase 2, Anchoring Strategy in Difficult-to-Control Type 2 Diabetes
Premium
Private Companies
Sparrow’s Clofutriben Shows Broad Metabolic Gains in Phase 2, Anchoring Strategy in Difficult-to-Control Type 2 Diabetes
3M ago
Sparrow Pharmaceuticals Advances Diabetes Pipeline With Upcoming ENDO 2026 Phase 2b Data
Premium
Private Companies
Sparrow Pharmaceuticals Advances Diabetes Pipeline With Upcoming ENDO 2026 Phase 2b Data
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100